Therapeutic effects of neurodynamic and active release technique in carpal tunnel syndrome

To compare the Therapeutic Effects of Neurodynamic and Active Release Techniques in Carpal Tunnel Syndrome.

It was a concealed, randomized, single blinded, sham controlled clinical trial with a parallel group design of 12 patients.

Study was conducted at Layyah city hospital of govt college university Faisalabad Layyah campus. The study population was consisted of patients with carpal tunnel syndrome. The study was single blinded. The participants didn't know while they were receiving experimental or conventional treatment

Inclusion Criteria: Age is between 25-50 years, both gender, complaints of pain, numbness or tingling in the first three digits, positive Phalen’s Sign and unilateral Compression of Nerve Exclusion Criteria: History of Carpal Tunnel Release Surgery, Patients with median nerve involvement in proximal areas such as thoracic outlet syndrome, cervical radiculopathy, Steroid injection in the carpal tunnel, thenar muscle atrophy, metabolic diseases such as diabetes, severe thyroid disorders, anemia and pregnancy

Participants will be randomly allocated into two groups (Group A: Neurodynamic group, Group B active release technique group). The participants randomly allocated in Group A will be received neural mobilizations. Participants will execute this training after 10 minutes of infrared. This approach requires three sessions per week for eight weeks. Group B participants will have received treatment includes infrared for 10 min and active release technique.

Disabilities of upper extremity (Disabilities of the arm, shoulder and hand questionnaire), Severity (Symptom Severity Scale)

Participants were randomized by using concealed envelope method. In this, sealed opaque envelops with treatment regimen written were provided to the participants. Once a patient had consented to enter a trial room, an envelope was opened, and the patient was then offered the allocated treatment.

Assessor will only assess the patient at baseline,4th week and at 8th week for treatment outcomes. Assessor safe the data for follow-up and will not share it with any therapist or patient. At any stage, the assessor is unaware of the treatment and control group. The study was single-blinded. The assessor was unaware of the treatment given to either groups 1 or 2

Demographic data and data related to final outcome will be shared by maintaining the confidentiality.

Data will be available from August 2024 to November 2024 after the 6 months of publication. The data sharing plan for a clinical trial (i.e., what data will be shared when and under what conditions) will be publicly available at a third-party site that shares data with and meets the data requirements of WHO's International Clinical Trials Registry Platform; this occur before the first participant is enrolled.

Deidentified IPD and any additional information will be shared for the people working in academic institution and clinical research writers.

for research purpose

To the corresponding author of the study, Dr Sania Naz and can contact on +923044407035 saaniaanaz@gmail.com can visit these search engines, you can find my study easily here https://www.researchgate.net/ https://scholar.google.com/

Open-access and there is the traditional public data release where anyone can get access to the data with no registration or conditions. The request will be reviewed by Director in Charge and in case of eligibility, it would be shared in two weeks.

I want randomized clinical trial registration.